Feider Stephen 4

What Happened

• Stephen Feider, Chief Financial Officer of Beta Bionics (BBNX), exercised stock options to acquire 9,878 shares (4,982 on 2026-06-26 and 4,896 on 2026-06-29) at an exercise price of $5.10 per share (total exercise cost ≈ $50,378). He also sold 10,000 shares in open-market transactions (5,104 on 2026-06-26 and 4,896 on 2026-06-29) for total gross proceeds of about $170,387 (weighted avg sale prices ≈ $17.05 and $17.03). Overall this sequence is an option exercise followed by sales (monetization), not an outright purchase.

Key Details

• Transaction dates: 2026-06-26 and 2026-06-29; Form 4 filed 2026-06-30 (appears timely — Form 4s are due within 2 business days of the transaction).
• Exercise details: 4,982 shares @ $5.10 (6/26) and 4,896 shares @ $5.10 (6/29).
• Sale details: 5,104 shares sold on 6/26 (weighted avg $17.0468; price range $17.00–17.12) and 4,896 shares sold on 6/29 (weighted avg $17.0304; range $17.00–17.08). Footnotes F2/F3 note full per-price breakdowns are available on request.
• Total exercised: 9,878 shares (total cost ≈ $50,378). Total sold: 10,000 shares (total proceeds ≈ $170,387).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Notable footnotes: F1 — sales were made pursuant to a Rule 10b5‑1 trading plan adopted May 15, 2025. F4 — the underlying option vests in 48 equal monthly installments from Sept 14, 2023. The filing also lists derivative "disposed" entries at $0, which reflect option conversion/cancellation on exercise.

Context

• These transactions show option exercises immediately followed by open‑market sales (i.e., monetization of vested options), and the sales were executed under a pre‑arranged 10b5‑1 plan. Such pre‑arranged-plan sales are routine and do not, by themselves, indicate the insider’s view of the company’s prospects.